• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三种预测指标鉴别卵巢恶性肿瘤与良性卵巢子宫内膜异位囊肿的比较:特征与效能

The Comparison of Three Predictive Indexes to Discriminate Malignant Ovarian Tumors from Benign Ovarian Endometrioma: The Characteristics and Efficacy.

作者信息

Yamanaka Shoichiro, Kawahara Naoki, Kawaguchi Ryuji, Waki Keita, Maehana Tomoka, Fukui Yosuke, Miyake Ryuta, Yamada Yuki, Kobayashi Hiroshi, Kimura Fuminori

机构信息

Department of Obstetrics and Gynecology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8522, Japan.

出版信息

Diagnostics (Basel). 2022 May 12;12(5):1212. doi: 10.3390/diagnostics12051212.

DOI:10.3390/diagnostics12051212
PMID:35626367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9140823/
Abstract

This study aimed to evaluate the prediction efficacy of malignant transformation of ovarian endometrioma (OE) using the Copenhagen Index (CPH-I), the risk of ovarian malignancy algorithm (ROMA), and the R2 predictive index. This retrospective study was conducted at the Department of Gynecology, Nara Medical University Hospital, from January 2008 to July 2021. A total of 171 patients were included in the study. In the current study, cases were divided into three cohorts: pre-menopausal, post-menopausal, and a combined cohort. Patients with benign ovarian tumor mainly received laparoscopic surgery, and patients with suspected malignant tumors underwent laparotomy. Information from a review chart of the patients’ medical records was collected. In the combined cohort, a multivariate analysis confirmed that the ROMA index, the R2 predictive index, and tumor laterality were extracted as independent factors for predicting malignant tumors (hazard ratio (HR): 222.14, 95% confidence interval (CI): 22.27−2215.50, p < 0.001; HR: 9.80, 95% CI: 2.90−33.13, p < 0.001; HR: 0.15, 95% CI: 0.03−0.75, p = 0.021, respectively). In the pre-menopausal cohort, a multivariate analysis confirmed that the CPH index and the R2 predictive index were extracted as independent factors for predicting malignant tumors (HR: 6.45, 95% CI: 1.47−28.22, p = 0.013; HR: 31.19, 95% CI: 8.48−114.74, p < 0.001, respectively). Moreover, the R2 predictive index was only extracted as an independent factor for predicting borderline tumors (HR: 45.00, 95% CI: 7.43−272.52, p < 0.001) in the combined cohort. In pre-menopausal cases or borderline cases, the R2 predictive index is useful; while, in post-menopausal cases, the ROMA index is better than the other indexes.

摘要

本研究旨在评估使用哥本哈根指数(CPH-I)、卵巢恶性肿瘤风险算法(ROMA)和R2预测指数对卵巢子宫内膜异位症(OE)恶变的预测效能。这项回顾性研究于2008年1月至2021年7月在奈良医科大学附属医院妇科进行。共有171例患者纳入研究。在本研究中,病例分为三个队列:绝经前、绝经后和联合队列。卵巢良性肿瘤患者主要接受腹腔镜手术,疑似恶性肿瘤患者则接受剖腹手术。收集了患者病历复查表中的信息。在联合队列中,多因素分析证实,ROMA指数、R2预测指数和肿瘤侧别被提取为预测恶性肿瘤的独立因素(风险比(HR):222.14,95%置信区间(CI):22.27−2215.50,p<0.001;HR:9.80,95%CI:2.90−33.13,p<0.001;HR:0.15,95%CI:0.03−0.75,p = 0.021)。在绝经前队列中,多因素分析证实,CPH指数和R2预测指数被提取为预测恶性肿瘤的独立因素(HR:6.45,95%CI:1.47−28.22,p = 0.013;HR:31.19,95%CI:8.48−114.74,p<0.001)。此外,在联合队列中,R2预测指数仅被提取为预测交界性肿瘤的独立因素(HR:45.00,95%CI:7.43−272.52,p<0.001)。在绝经前病例或交界性病例中,R2预测指数有用;而在绝经后病例中,ROMA指数优于其他指数。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/923a/9140823/88139f4cc4ab/diagnostics-12-01212-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/923a/9140823/3452d45fbfe5/diagnostics-12-01212-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/923a/9140823/debd166e0da1/diagnostics-12-01212-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/923a/9140823/48bc9b4e3839/diagnostics-12-01212-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/923a/9140823/88139f4cc4ab/diagnostics-12-01212-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/923a/9140823/3452d45fbfe5/diagnostics-12-01212-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/923a/9140823/debd166e0da1/diagnostics-12-01212-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/923a/9140823/48bc9b4e3839/diagnostics-12-01212-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/923a/9140823/88139f4cc4ab/diagnostics-12-01212-g004.jpg

相似文献

1
The Comparison of Three Predictive Indexes to Discriminate Malignant Ovarian Tumors from Benign Ovarian Endometrioma: The Characteristics and Efficacy.三种预测指标鉴别卵巢恶性肿瘤与良性卵巢子宫内膜异位囊肿的比较:特征与效能
Diagnostics (Basel). 2022 May 12;12(5):1212. doi: 10.3390/diagnostics12051212.
2
A Novel Predictive Tool for Discriminating Endometriosis Associated Ovarian Cancer from Ovarian Endometrioma: The R2 Predictive Index.一种用于区分子宫内膜异位症相关卵巢癌与卵巢子宫内膜异位囊肿的新型预测工具:R2预测指数
Cancers (Basel). 2021 Jul 29;13(15):3829. doi: 10.3390/cancers13153829.
3
The Endometriotic Neoplasm Algorithm for Risk Assessment (e-NARA) Index Sheds Light on the Discrimination of Endometriosis-Associated Ovarian Cancer from Ovarian Endometrioma.用于风险评估的子宫内膜异位症肿瘤算法(e-NARA)指数有助于区分子宫内膜异位症相关卵巢癌与卵巢子宫内膜瘤。
Biomedicines. 2022 Oct 24;10(11):2683. doi: 10.3390/biomedicines10112683.
4
Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study.哥本哈根指数与 ROMA 在术前卵巢恶性肿瘤风险分层中的比较:来自越南首个前瞻性队列研究的结果。
Gynecol Oncol. 2021 Jul;162(1):113-119. doi: 10.1016/j.ygyno.2021.05.001. Epub 2021 May 14.
5
Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?比较哥本哈根指数(CPH-I)和卵巢恶性肿瘤风险算法(ROMA):在手术前区分良恶性卵巢肿瘤的两种等效方法?
Gynecol Oncol. 2016 Mar;140(3):481-5. doi: 10.1016/j.ygyno.2016.01.023. Epub 2016 Jan 26.
6
Diagnostic performances of the Ovarian Adnexal Reporting and Data System, the Risk of Ovarian Malignancy Algorithm, and the Copenhagen Index in the preoperative prediction of ovarian cancer: a prospective cohort study.卵巢附件报告和数据系统、卵巢恶性肿瘤风险算法及哥本哈根指数在卵巢癌术前预测中的诊断性能:一项前瞻性队列研究。
J Gynecol Oncol. 2025 Mar;36(2):e30. doi: 10.3802/jgo.2025.36.e30. Epub 2024 Sep 24.
7
Copenhagen index (CPH-I) is more favorable than CA125, HE4, and risk of ovarian malignancy algorithm (ROMA): Nomogram prediction models with clinical-ultrasonographic feature for diagnosing ovarian neoplasms.哥本哈根指数(CPH-I)比CA125、人附睾蛋白4(HE4)以及卵巢恶性肿瘤风险算法(ROMA)更具优势:基于临床超声特征的列线图预测模型用于诊断卵巢肿瘤。
Front Surg. 2023 Jan 13;9:1068492. doi: 10.3389/fsurg.2022.1068492. eCollection 2022.
8
Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors.比较哥本哈根指数与 ROMA 对卵巢肿瘤患者的术前评估。
Int J Gynaecol Obstet. 2018 Feb;140(2):241-246. doi: 10.1002/ijgo.12371. Epub 2017 Nov 22.
9
Serological and immunohistochemical biomarkers for discrimination between benign and malignant ovarian tumors.用于鉴别卵巢良性和恶性肿瘤的血清学及免疫组化生物标志物。
Rom J Morphol Embryol. 2019;60(4):1163-1174.
10
Diagnostic performance of CA125, HE4, ROMA, and CPH-I in identifying primary ovarian cancer.CA125、HE4、ROMA和CPH-I在识别原发性卵巢癌中的诊断性能。
J Obstet Gynaecol Res. 2023 Mar;49(3):998-1006. doi: 10.1111/jog.15540. Epub 2023 Jan 6.

引用本文的文献

1
Diagnostic value of the Risk of Ovarian Malignancy Algorithm (ROMA) index in the detection of ovarian cancer in postmenopausal women: a systematic review and meta-analysis.卵巢恶性肿瘤风险评估算法(ROMA)指数在绝经后女性卵巢癌检测中的诊断价值:一项系统评价和荟萃分析
BMC Womens Health. 2025 Jun 5;25(1):280. doi: 10.1186/s12905-025-03766-4.
2
New insights about endometriosis-associated ovarian cancer: pathogenesis, risk factors, prediction and diagnosis and treatment.子宫内膜异位症相关卵巢癌的新见解:发病机制、危险因素、预测、诊断与治疗
Front Oncol. 2024 Feb 7;14:1329133. doi: 10.3389/fonc.2024.1329133. eCollection 2024.
3

本文引用的文献

1
Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors.HE4、CA125、ROMA和CPH-I用于附件肿瘤术前评估的比较
Diagnostics (Basel). 2022 Jan 17;12(1):226. doi: 10.3390/diagnostics12010226.
2
Rethinking endometriosis and pelvic pain.重新审视子宫内膜异位症与盆腔疼痛。
J Clin Invest. 2021 Oct 15;131(20). doi: 10.1172/JCI154876.
3
A Novel Predictive Tool for Discriminating Endometriosis Associated Ovarian Cancer from Ovarian Endometrioma: The R2 Predictive Index.一种用于区分子宫内膜异位症相关卵巢癌与卵巢子宫内膜异位囊肿的新型预测工具:R2预测指数
Case Series and a Literature Review: Two Ovarian Clear Cell Carcinoma Cases with Recurrent Endometriosis.
病例系列及文献综述:两例合并复发性子宫内膜异位症的卵巢透明细胞癌病例
Int J Womens Health. 2023 Oct 24;15:1611-1619. doi: 10.2147/IJWH.S418135. eCollection 2023.
4
The Endometriotic Neoplasm Algorithm for Risk Assessment (e-NARA) Index Sheds Light on the Discrimination of Endometriosis-Associated Ovarian Cancer from Ovarian Endometrioma.用于风险评估的子宫内膜异位症肿瘤算法(e-NARA)指数有助于区分子宫内膜异位症相关卵巢癌与卵巢子宫内膜瘤。
Biomedicines. 2022 Oct 24;10(11):2683. doi: 10.3390/biomedicines10112683.
Cancers (Basel). 2021 Jul 29;13(15):3829. doi: 10.3390/cancers13153829.
4
External Validation of the IOTA Classification in Women with Ovarian Masses Suspected to Be Endometrioma.IOTA分类法在疑似卵巢子宫内膜异位囊肿女性中的外部验证
J Clin Med. 2021 Jul 1;10(13):2971. doi: 10.3390/jcm10132971.
5
Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation-A nationwide case-control study.子宫切除术后、输卵管切除术和输卵管结扎术后 I 型和 II 型卵巢上皮癌的风险:一项全国范围内的病例对照研究。
Int J Cancer. 2021 Oct 15;149(8):1544-1552. doi: 10.1002/ijc.33714. Epub 2021 Jul 7.
6
Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study.哥本哈根指数与 ROMA 在术前卵巢恶性肿瘤风险分层中的比较:来自越南首个前瞻性队列研究的结果。
Gynecol Oncol. 2021 Jul;162(1):113-119. doi: 10.1016/j.ygyno.2021.05.001. Epub 2021 May 14.
7
Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes.卵巢癌的液体活检:在无声杀手来袭之前将其捕获。
World J Clin Oncol. 2020 Nov 24;11(11):868-889. doi: 10.5306/wjco.v11.i11.868.
8
Emerging Role of Metabolomics in Ovarian Cancer Diagnosis.代谢组学在卵巢癌诊断中的新兴作用
Metabolites. 2020 Oct 19;10(10):419. doi: 10.3390/metabo10100419.
9
Comparison of Risk of Ovarian Malignancy Algorithm and cancer antigen 125 to discriminate between benign ovarian tumor and early-stage ovarian cancer according to imaging tumor subtypes.根据影像学肿瘤亚型,比较卵巢恶性肿瘤风险算法和癌抗原125在鉴别良性卵巢肿瘤与早期卵巢癌方面的作用。
Oncol Lett. 2020 Jul;20(1):931-938. doi: 10.3892/ol.2020.11629. Epub 2020 May 14.
10
Mitochondria Participate in Chemoresistance to Cisplatin in Human Ovarian Cancer Cells.线粒体参与人卵巢癌细胞顺铂耐药。
Mol Cancer Res. 2020 Sep;18(9):1379-1391. doi: 10.1158/1541-7786.MCR-19-1145. Epub 2020 May 29.